Biotechnology

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China

SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...

2020-10-27 08:13 2378

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside ofGreater China * Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to global patient communities by partnering ...

2020-10-27 07:23 3515

Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

* SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance * Both doses were shown to be superior to placebo for key secondary endpoints * AEs were manageable and generally transient and r...

2020-10-26 19:40 1432

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

HYDERABAD, India, Oct. 26, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations  (CRDMO), ...

2020-10-26 16:35 2192

RhoVac Participates in BIO Europe Digital

LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that it is participating this week in the partnering event BIO Europe 2020 Digital. This week the digital version of the massive pharmaceutical partnering conference BIO Europe is held with participation from RhoVac...

2020-10-26 16:26 1497

PharmAbcine to participate at BIO-Europe 2020

DAEJEON, South Korea, Oct. 23, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will participate in the 26th Annual International BIO-Europe Partnering Conference which will be held digitally from October 26th to 29th. PharmAbcine's business development ...

2020-10-23 20:00 10385

TUV Rheinland Announces the Opening of its NABL Accredited Biomaterial and EMC Testing Laboratories

VISAKHAPATNAM, India, Oct. 23, 2020 /PRNewswire/ -- TUV Rheinland, a global leader in independent technical services announced the opening of its Biomaterial and EMC (Electro Magnetic Compatibility) Testing Laboratories located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, Andhra Pradesh....

2020-10-23 09:15 2469

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

PROVIDENCE, Rhode Island, Oct. 22, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year,$1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug ...

2020-10-22 21:00 2517

Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe Atopic Dermatitis (AD) at EADV Virtual Meeting

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 22, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune and inflammatory diseases, today announced it wil...

2020-10-22 19:30 1764

Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement

SHANGHAI, Oct. 22, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced that it has signed a definitive merger agreement with 4D pharma PLC (AIM: DDDD, "4D pharma" or "4D"). Upon co...

2020-10-22 14:00 9269

Samsung Biologics' strategic business operations continue to support strong third quarter earnings

INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...

2020-10-21 19:00 8173

Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...

2020-10-21 17:37 2286

Cyclica to use Excelra's GOSTAR Database to develop AI & ML based Deep Learning Algorithm for Drug Target Identification

HYDERABAD, India and TORONTO, Oct. 21, 2020 /PRNewswire/ -- Excelra , a leading global Data & Analytics organization, today announced that it has licensed its Global Online Structure Activity Relationship Database (GOSTAR) to Cyclica Inc., a leading biotechnology company...

2020-10-21 10:00 4616

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end - ahead of schedule

HELSINKI, Finland, Oct. 21, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform "), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform's proprietary CESS® technology. Dosing will ...

2020-10-21 02:14 4267

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clini...

2020-10-20 19:00 9339

Key patent granted for Isla101 in Brazil

MELBOURNE, Australia, Oct. 20, 2020 /PRNewswire/ -- Isla Pharmaceuticals, a US-based company focused on rational repurposing of molecules for the treatment or prevention of viruses is pleased to announce that a key patent relating to the Company's lead program, Isla101 has been granted by the Bra...

2020-10-20 03:15 2002

Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing

INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. Under this agreement, Samsung Biologics will provide a full scope of its ...

2020-10-19 19:00 10239

Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference

* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...

2020-10-16 20:00 18266

analytica 2020 - free entry from the computer

Messe München and LUMITOS stage the largest virtual event of the year for the lab industry BERLIN, Oct. 16, 2020 /PRNewswire/ -- analytica, the world's leading trade fair for laboratory technology, analysis and biotechnology, will take place completely virtually in 2020. Visitors and exhibitors ...

2020-10-16 17:29 3661

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participat...

2020-10-16 07:30 12565
1 ... 272273274275276277278 ... 306